COST ANALYSIS OF ORAL ANTIHYPERTENSIVE DRUGS: ASSESSING THE EFFECT OF DRUG PRICE CONTROL ORDER IN INDIA

Himanshu Sharma; Amit Kumar; Samarjeet  Kaur; Jayvardhan Singh; Garima Sharma

doi:10.22159/ajpcr.2022.v15i9.46092

Authors

Himanshu Sharma Department of Pharmacology, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India.
Amit Kumar Department of Pharmacology, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India.
Samarjeet Kaur Department of Community Medicine, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India.
Jayvardhan Singh Department of Physiology, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India.
Garima Sharma Department of Pathology, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i9.46092

Keywords:

Oral Antihypertensives, Drug price control order, National pharmaceutical pricing authority, Cost ratio, Cost variation

Abstract

Objective: The study focuses on cost analysis of different available brands of oral antihypertensive drugs in India and assesses compliance with their ceiling prices fixed by drug price control order (DPCO).

Methods: This is an observational study conducted in the Department of Pharmacology, GSVM Medical College Kanpur, from May to June 2022. The ceiling price of oral antihypertensive drugs was obtained from the DPCO price list 2021 and dosage and prices of the different brands of antihypertensive drugs available in India were obtained from medguideindia.com and Current Index of Medical Specialities-CIMS (Jan–April 2022 edition, India). Thereafter, data analysis of oral antihypertensive drugs was done on Microsoft Excel Office 2019 version.

Results: Our study found a total 1575 brands of oral antihypertensive drugs available in market, 34% brands were having prices more than DPCO recommended ceiling price. Maximum price violation was noticed with capsule nifedipine 10 mg (83.33%) and tablet telmisartan 80 mg (60.98%). The maximum cost variation and cost ratio was seen with tablet propranolol 10 mg, that is, 3233.33% and 33.33, respectively, followed by tablet amlodipine 5 mg, that is, 2123.33% and 22.23.

Conclusion: Stringent regulation and monitoring of the DPCO price list should be done to ensure that all drugs and especially oral antihypertensive drugs are not sold above the ceiling price set by the order so that the compliance for the drugs is optimized and India could achieve its objective of reducing the prevalence of hypertension to <25% by 2025.

Downloads

Download data is not yet available.

References

Gupta R, Xavier D. Hypertension: The most important non-communicable disease risk factor in India. Indian Heart J 2018;70:565-72.

Ramakrishnan S, Zachariah G, Gupta K, Rao JS, Mohanan PP, Venugopal K, et al. Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey. Indian Heart J 2019;71:309-13.

Available from: https://www.who.int/india/health-topics/hypertension

Sandozi T, Emani VK. Survey of a prescription pattern of anti-hypertensive drugs in hypertensives and hypertension-associated diabetics. Int J Pharm Bio Sci 2010;1:23-6.

Gazette of India-Extraordinary Part II-Sec. 3 (ii). Drugs Price Control Order. New Delhi: Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals (National Pharmaceuticals Pricing Authority); 2013. Available from: https://www.pharmaceuticals.gov.in/dpco2013gaz.pdf

Drug Price Control Order 2013-National Pharmaceutical Pricing Authority; 2013. Available from: https://www.nppaindia.nic.in/ DPCO2013.pdf

Drug Price Control Order Price List; 2021. Available from: https://www. nppaindia.nic.in/wp-content/uploads/2021/03/3_866_Engl_CP.pdf

MedGuide India. Available from: https://www.medguideindia.info/ show_generics.php

Trask L. Pharmacoeconomics: Principles, methods, and applications. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L, editors. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2011.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort-Hasen K, editors. A Textbook of Clinical Pharmacy Practice. 1st ed. Himayatnagar, Hyderabad: Orient Longman; 2004. p. 72-3.

Kardas P, Bishai WR. Compliance in infective medicine. Adv Stud Med 2006;6:652-8.

Piette JD, Beard A, Rosland AM, McHorney CA. Beliefs that influence cost-related medication nonadherence among the “haves” and “have nots” with chronic diseases. Patient Prefer Adherence 2011;5:389-96.

Kumar A, Sharma H, Shivhare DP, Singh J. Drug prescribing pattern in dermatology outpatient department at a tertiary care teaching hospital of North India-a cross-sectional survey-based study. Natl J Physiol Pharm Pharmacol 2022;12:903-6.

Kumar R, Kumar N, Ahmad A, Kumar M, Rajendra N, Dixit RK, et al. Cost comparison of antihypertensive drugs available in India with drugs prices control order price list. Int J Res Med Sci 2019;7:101-5.

Kamath L, Satish GR. Cost variation analysis of antihypertensive drugs available in Indian market: An economic perspective. Int J Pharm Sci Res 2016;7:2050-56.

Karve AV, Chattar KB. Cost analysis study of oral antihypertensive agents available in the Indian market. Int J Basic Clin Pharmacol 2014;3:479-83.

Deolekar P. Cost-effectiveness analysis of antihypertensive drugs available in the Indian market. World J Pharm Res 2017; ???:833-40.